Novel Pulmonary Delivery of Drugs for the Management of Atrial Fibrillation

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia worldwide and is associated with increased mortality and decreased quality of life through its complications such as heart failure and stroke [1, 2]. It has been reported that more than 335 million people are suffering from AF globally [3]. More importantly, the incidence is rapidly rising owing to changing lifestyles and an increasingly aging global population. AF results from abnormal electrical impulses in the atria, and the passing of these irregular signals to the ventricles results in a rapid and abnormal heartbeat. While the exact cause of AF is uncertain, common risk factors include coronary artery disease, hypertension, cardiomyopathies and valvular heart disease, along with other comorbidities that impact the heart. Contemporary drug management of AF using currently available oral anti-arrhythmic drugs has a relatively slow onset of action, which reduces their effectiveness for management of acute episodes of rapid AF, while rapid-onset intravenous formulations often require hospitalization and intravenous cannulation for drug administration and monitoring of adverse effects. AF can lead to thromboembolic phenomena such as stroke or myocardial infarction [4]. Oral vitamin K antagonist (warfarin) and novel non-vitamin K antagonist oral anticoagulant (NOAC) drugs substantially reduce the risk of thrombus formation and clinical sequalae such as stroke [5‐7]. The use of these drugs in clinical practice remains challenging as long-term use of oral anticoagulants has the potential to cause dose-related gastrointestinal bleeding and fatal intracranial hemorrhage. To overcome these limitations and complexities, an alternative drug delivery system, such as the pulmonary route of anti-arrhythmic and anticoagulant delivery, may be considered, as this route of drug delivery can produce rapid onset of action and efficient therapeutic benefits at very low doses [8, 9]. Pulmonary drug delivery avoids first-pass metabolism of drugs and any associated toxicities typical to oral dosage forms. The inhaled drug delivery system may also be used as an efficient route for delivering drugs, having systemic activity owing to the lungs’ large surface area, with thin vasculature for drug absorption, and therapeutic action at a greatly low dose. Therefore, this mini-review will briefly discuss the pathophysiology of AF as well as the available treatment options and their limitations. Finally, it will highlight and discuss the benefits of inhaled drug delivery for improved therapeutic benefits in AF at a much lower dose compared with those required for oral drug delivery.

Emerging evidence suggests that several pathophysiological mechanisms may underlie AF, including structural and electrical abnormalities, tissue remodeling and inflammation [10]. It is well recognized that when the atrial tissue develops electrical or structural defects, the atrial contractions become irregular, with an uncoordinated flow of blood into the ventricles. Thus, AF can contribute to large variations in blood pressure and cardiac output. Furthermore, several triggers, like single rapidly firing foci in the atria, may cause AF [10], which ultimately produces fibrillatory conduction through the heart [10]. Several studies have reported that this rapid focus firing occurs most frequently in the pulmonary veins, which can instigate repetitive firing or, in some cases, episodic re-entrant activation of the foci in the veins [11]. The exact mechanisms underlying AF initiation due to rapid firing have not been well understood; however, they may involve increased automaticity, micro-reentry or triggered activity [12]. Additionally, the focal rapid firing activity in the atria seems to be the cause of paroxysmal AF and is the rationale behind pulmonary vein isolation as a treatment option. Fibrosis in the atria was reported to create abnormal substrates that can further prolong AF and promote ectopic activity and/or re-entry [13], which can potentially induce the creation of re-entrant circuits that will further propagate AF. Moreover, electrophysiological changes can also occur within minutes of AF onset, shortening the refractory period and increasing the likelihood of persistent AF. Multiple risk factors have been identified to increase the risk of AF, including genetic factors, obesity, extreme endurance exercise and alcohol and caffeine consumption [10].

Studies in developing advanced drug delivery technology have not progressed for the treatment of AF. The sub-optimal nature of current treatment strategies for AF presents the need to develop more efficient and advanced options that may help to eliminate some of the many adverse effects seen by traditional therapy. Recently, cardiovascular gene therapy has been explored as a potential alternative over typical drugs and catheter-based ablation therapies. Several gene therapy targets have already been identified as relevant to the control of rate or rhythm of the heart during AF. For rate control, through genetic modification of the atrioventricular node, there is a proposed reduced conduction and thus ventricular response rate to AF [4]. The proposed vector would be delivered by arterial perfusion, which is desirable as there is minimal invasiveness and the method is practical with current standard clinical approaches. A disadvantage, however, is the limited efficacy involved with whole nodal transduction [4]. Rhythm control through modification of atrial muscle to become a substrate less supportive of AF has also been investigated [20]. Many studies so far have been conducted in large animal models, making the easy transition to human studies more promising than the outcomes obtained from small animals. However, the vector used (such as adenovirus) can present limitations such as the induction of strong inflammatory responses and subsequent clearance of the vector and limits gene expression [4].

Pulmonary drug delivery technology is the most suitable route of drug administration as it delivers drugs deep into the lungs, avoids first-pass metabolism and produces therapeutic benefits at a very low dose of the delivered drugs (Fig. 1). Currently, oral medications for the management of AF have a relatively slow onset of action and are also associated with dose-related adverse effects. There are three main categories of device available for lung delivery of drugs, i.e., metered dose inhalers (MDIs) (Fig. 1a), dry powder inhalers (DPIs) (Fig. 1b) and nebulizers. The MDI formulations are solutions or suspensions of drugs in liquified hydrofluoroalkane or propellant. The DPI formulations consist of either the agglomerated forms of the micronized drug particles (< 5 µm) with controlled flow properties or the large carrier-based powder mixtures. The micronized drug particles (< 5 µm) are highly cohesive with reduced flowability, which affects the aerosolization performance of the powder. Therefore, large carriers (preferably lactose powder) are used to enhance the flowability of the formulations. The nebulizer formulations are aqueous solutions or suspensions of drugs, which are delivered as a large dose. As presented in Fig. 1, the lung-deposited drug can be translocated into the heart through the air–blood pulmonary barrier, avoiding first-pass metabolism and any associated toxicities typical to oral ingestion. Furthermore, the profuse vascular nature of the lungs, as well as relatively low levels of proteolytic enzymes, presents the opportunity for the drug to enter the systemic system more rapidly at very low doses compared to those required for oral delivery [21]. A successful drug would have both an appropriate inhalable formulation [22, 23] and stable aerodynamic properties [24]. Factors such as the varying anatomy between human respiratory tracts, inhalation flow rate and drug particle size (< 5 µm) must also be considered for the efficient delivery of drug. The drug particle size must be < 5 µm for efficient delivery of the drug deep into lungs for appropriate absorption. Effective drug delivery to the lungs using inhaled formulations is dependent on the drug particle formulation, the delivery device and the patient’s inhalation force.

The inhaled route, with potential advantages for delivering antiarrhythmic drugs for rapid conversion of AF, is progressing [25]. Preclinical and clinical studies of the inhaled drugs for potential application in the management of AF are summarized in Table 1.

Among the antiarrhythmic drugs, flecainide is the most investigated drug for pulmonary delivery, with significant success in preclinical studies [25‐30]. Tessarolo et al. demonstrated that the intratracheal instillation of flecainide rapidly terminated AF through multimodal effects such as slowing down of atrial conduction velocity and decreasing AF frequency at a reduced dose [31]. Inhaled cyclodextrin complexed flecainide formulation was found to accelerate the conversion of AF to sinus rhythm in a dose-dependent mode and shortened the duration of AF. The authors suggested that flecainide complexed with cyclodextrin formulation effectively terminated AF by slowing down the atrial conduction velocity as well as decreasing the frequency of AF. The peak plasma level of flecainide complexed cyclodextrin formulation was achieved within 2 min of intratracheal instillation. The authors emphasized that the rapid increase in plasma drug levels upon inhalation optimized its anti-AF effects at a low dose, with reduced adverse effects versus an oral formulation. These excellent outcomes proved the applicability of inhaled formulations for the efficient management of AF. Intratracheal instillation of this drug in Yorkshire pigs showed fast absorption of the delivered drug and increased the concentration of drug in pulmonary veins and the left atrium, resulting in the termination of AF [26]. Marum et al. [29] investigated the reduction of AF by rapid administration of a low dose of flecainide, by intratracheal or intravenous routes in pig models. They found a similar reduction of AF duration with both intratracheal and intravenous administration of the drug. The authors concluded that the rapid delivery (inhalation or intravenous) of a low dose of flecainide optimized the plasma drug concentration profile for effective conversion of AF. In Stocco et al.’s study, low-dose inhaled flecainide was shown to allow flecainide to reach systemic circulation in 2 min, with a pharmacokinetic profile similar to that of an intravenous route. The authors concluded that the inhaled flecainide was safe and well tolerated [28]. The outcomes of the above investigations indicate that the pulmonary delivery of flecainide is a promising avenue in the therapeutic approach for the treatment of AF.

The clinical application of flecainide has recently been investigated in 101 patients with symptomatic onset of AF less than 48 h. An inhaled 120-mg dose produced cardioconversion in 48% of the patients 8 min after the end of inhalation [32]. The peak plasma concentration (386 ± 209 ng/mL) occurred with a 120-mg dose within 3 min of inhalation. This is the first clinical study to reveal that inhaled flecainide has the potential to be a practical application for rapid conversion of AF to sinus rhythm. A comprehensive phase 3 clinical trial (identifier # NCT05039359) involving 400 participants is ongoing, and more data will be published in future.

The pulmonary delivery of the beta-adrenergic blocker metoprolol was found to terminate AF in a pig model [30]. The authors demonstrated that the inhaled metoprolol efficiently reduced the ventricular rate and enhanced conversion to normal sinus rhythm. Additionally, the inhaled metoprolol was also found to reduce AF dominant frequency by 31% compared to that of control (sterile water). Belardinelli et al. patented the inhaled formulations of metoprolol and flecainide for the treatment of heart conditions such as cardiac arrhythmia, atrial arrhythmia and AF [33]. Further details of the inhaled antiarrhythmic drugs for rapid changes of AF have been reported [25].

Recently, inhalation of < 50-nm calcium phosphate (CaP) nanoparticles loaded with a peptide dyed with cyanine 7 (Cy7) was found to show rapid translocation of CaP from the pulmonary tree to the bloodstream and to the myocardium, where the peptide was released very quickly in an animal model [34]. The authors demonstrated that drug administration via inhalation was a more efficient delivery method in the rapid delivery of Cy7-loaded CaP to the myocardium compared to oral and parenteral delivery. Oral delivery did not get the drug into the target 40 min after administration. This is a very encouraging effect of the inhaled drug delivered into the heart via the lungs and is considered a pioneering method for the management of heart diseases. Inhaled amiodarone was found to induce transient pulmonary inflammation with little damage to the lungs of Wistar rats [35]; however, further investigations are warranted to understand the suitability of the inhaled delivery of this drug to overcome the dose-related adverse effects of oral administration.

Pulmonary delivery of anticoagulants was demonstrated to be a safe and beneficial route for treatment [36‐38]. Very recently, Abdur Rashid et al. developed inhaled edoxaban (EDX), which showed very promising anticoagulation effects at a greatly reduced concentration (3 μg/mL) in 20 min [8]. It can be highlighted that the required therapeutic concentration of 256 ng/mL (0.26 μg/mL), which is obtained from 60 mg of orally administered EDX, can be attained by lung delivery of 208–309 μg of EDX for anticoagulation effect. Lung delivery of heparin for idiopathic pulmonary fibrosis (IPF) is well documented [37]. Inhaled low molecular weight heparin (LMWH) from DPI formulations has been reported as an alternative to multiple parenteral administration [39]. Additionally, the DPI formulation of LMWH showed better absorption compared to that of an inhalable solution formulation [40]. The DPI formulation produced an approximately 1.5-fold increase in the bioavailability (41.6%) compared to the liquid formulation (32.5%). Inhaled anticoagulant therapy in both preclinical and clinical studies was found to increase the survival of the patients and decrease the morbidity [41]. Inhaled heparin was also found to be effective and safe for the patients with asthma and chronic obstructive pulmonary disease (COPD). The pulmonary route for unfractionated heparin delivery was also reported as the most suitable for obtaining anti-inflammatory, antioxidant and mucolytic effects in the patients with asthma and COPD [42].

Currently available medications for the management of AF have a relatively slow onset of action and require high doses via the oral route, which causes an increase in drug concentration in the systemic circulation, with considerably long elimination half-lives that together result in dose-related adverse effects. This mini-review has demonstrated the possibility of developing an inhaled drug delivery system for the treatment of AF at very low doses, which potentially can achieve a rapid therapeutic effect and significantly reduce the dose-related adverse effects seen with oral drug delivery. Although preclinical studies and some clinical studies have been performed, wider clinical investigations are warranted to draw a comprehensive conclusion. Based on the evidence presented, we believe that this novel delivery approach will have significantly improved efficacy and clinical outcomes over current strategies in the management of AF.